JP2007519739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519739A5 JP2007519739A5 JP2006551478A JP2006551478A JP2007519739A5 JP 2007519739 A5 JP2007519739 A5 JP 2007519739A5 JP 2006551478 A JP2006551478 A JP 2006551478A JP 2006551478 A JP2006551478 A JP 2006551478A JP 2007519739 A5 JP2007519739 A5 JP 2007519739A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- diabetes
- antibody
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53955004P | 2004-01-27 | 2004-01-27 | |
| US56649904P | 2004-04-29 | 2004-04-29 | |
| PCT/US2005/002609 WO2005072385A2 (en) | 2004-01-27 | 2005-01-27 | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519739A JP2007519739A (ja) | 2007-07-19 |
| JP2007519739A5 true JP2007519739A5 (https=) | 2008-05-01 |
Family
ID=34830483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551478A Pending JP2007519739A (ja) | 2004-01-27 | 2005-01-27 | 下垂体細胞アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｃａｐ２）アゴニストおよびそれらの製薬学的使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090143283A1 (https=) |
| EP (1) | EP1713493A4 (https=) |
| JP (1) | JP2007519739A (https=) |
| KR (1) | KR20070009554A (https=) |
| AU (1) | AU2005208911A1 (https=) |
| BR (1) | BRPI0507177A (https=) |
| CA (1) | CA2554475A1 (https=) |
| EC (1) | ECSP066793A (https=) |
| IL (1) | IL176705A0 (https=) |
| MA (1) | MA28335A1 (https=) |
| NO (1) | NO20063801L (https=) |
| RU (1) | RU2006130691A (https=) |
| WO (1) | WO2005072385A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123109A2 (en) * | 2004-06-12 | 2005-12-29 | Bayer Pharmaceuticals Corporation | Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use |
| JP2008539723A (ja) * | 2005-05-06 | 2008-11-20 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法 |
| BRPI0617740A2 (pt) * | 2005-10-26 | 2011-08-02 | Lilly Co Eli | agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| CA2982861A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| EP3426288A4 (en) | 2016-04-15 | 2019-10-30 | Alder Biopharmaceuticals, Inc. | ANTI-PACAP ANTIBODIES AND USES THEREOF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU656230B2 (en) * | 1991-10-11 | 1995-01-27 | F. Hoffmann-La Roche Ag | Cyclic vasoactive peptides |
| RU2269354C2 (ru) * | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
| CA2472956A1 (en) * | 2002-02-14 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| HN2003000217A (es) * | 2002-07-12 | 2004-07-26 | Bayer Pharmaceuticals Corp | Agonistas del receptor (vpac2) del peptido activamente de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologico. |
-
2005
- 2005-01-27 AU AU2005208911A patent/AU2005208911A1/en not_active Abandoned
- 2005-01-27 BR BRPI0507177-1A patent/BRPI0507177A/pt not_active IP Right Cessation
- 2005-01-27 CA CA002554475A patent/CA2554475A1/en not_active Abandoned
- 2005-01-27 US US10/586,124 patent/US20090143283A1/en not_active Abandoned
- 2005-01-27 JP JP2006551478A patent/JP2007519739A/ja active Pending
- 2005-01-27 EP EP05712166A patent/EP1713493A4/en not_active Withdrawn
- 2005-01-27 WO PCT/US2005/002609 patent/WO2005072385A2/en not_active Ceased
- 2005-01-27 RU RU2006130691/15A patent/RU2006130691A/ru not_active Application Discontinuation
- 2005-01-27 KR KR1020067015124A patent/KR20070009554A/ko not_active Withdrawn
-
2006
- 2006-07-04 IL IL176705A patent/IL176705A0/en unknown
- 2006-07-24 MA MA29206A patent/MA28335A1/fr unknown
- 2006-08-25 EC EC2006006793A patent/ECSP066793A/es unknown
- 2006-08-25 NO NO20063801A patent/NO20063801L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baetta et al. | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences | |
| US10603283B2 (en) | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| TWI432200B (zh) | 二肽基肽酶抑制劑之投予 | |
| Gallwitz | Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | |
| Hanefeld | Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes | |
| Pal et al. | MDR-and CYP3A4-mediated drug–drug interactions | |
| KR102062824B1 (ko) | 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도 | |
| RU2600440C2 (ru) | Твердые композиции, содержащие агонист glp-1 и соль n-(2-гидроксибензоил)амино)каприловой кислоты | |
| TWI609702B (zh) | 層狀醫藥調配物 | |
| Van Heiningen et al. | Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing | |
| Kim et al. | Pharmaceutical application and development of fixed-dose combination: dosage form review | |
| JP2006506969A5 (https=) | ||
| KR20100093055A (ko) | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 | |
| KR20080040643A (ko) | 의약의 병용 및 그 용도 | |
| KR20200013100A (ko) | 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 | |
| KR20110040883A (ko) | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 | |
| EA037712B1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
| Lau et al. | Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function | |
| US11266652B2 (en) | Methods of treating subjects having diabetes with chronic kidney disease | |
| JP2007519739A5 (https=) | ||
| Seong et al. | Pharmacokinetic drug interactions between amlodipine, valsartan, and rosuvastatin in healthy volunteers | |
| Sridhar et al. | Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review | |
| Mohsen et al. | Recent therapeutic targets in diabetic nephropathy | |
| KR20170123704A (ko) | 제2형 당뇨병 환자의 치료 | |
| Li et al. | Self-assembling peptides improve the stability of glucagon-like peptide-1 by forming a stable and sustained complex |